On February 4, 2016 RIBOXX PHARMACEUTICALS, a biotech company developing Toll-like-receptor (TLR) and RIG-I-like-Receptor (RLR) ligands, and TOLLYS SAS, a biotech company developing new therapeutic strategies in cancer, reported that they have signed a license agreement that grants TOLLYS exclusive global development and commercialization rights to a new drug development program, which RIBOXX will refer to as APOXXIM (Press release, Riboxx Pharmaceuticals, FEB 4, 2016, View Source [SID:1234508983]). Schedule your 30 min Free 1stOncology Demo! Under the terms of the license agreement, TOLLYS will assume sole responsibility for global development and commercialization of APOXXIM product candidate. Riboxx will be responsible for manufacturing and supply of APOXXIM to TOLLYS.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
APOXXIM is a Toll-like Receptor 3 (TLR3)-ligand that eliminates cancer cells by activating the TLR3 pathway. APOXXIM displays unique physico-chemical and biological properties, as well as optimal biodisponibility with increased stability to degradation in body fluids such as human plasma. APOXXIM is manufactured with the unique patented cGMP TENPORA-Process of Riboxx.
Jacques Rohayem, CEO and CSO of RIBOXX PHARMACEUTICALS declared: "We are very thrilled to start this collaboration with TOLLYS, a company with a very strong scientific expertise in cancer therapy. This collaboration expands the portfolio of Riboxx drug development programs such as RIBOXXIM, RIBOXXOL and QUADROXXIM, mainly focusing on cancer immunotherapy."
Jacques-François Martin, President of TOLLYS declared: "TOLLYS is very pleased to start this collaboration towards the development of a new and unique therapeutic strategy in cancer. The potential of TLR3-Ligands such as APOXXIM to treat cancer has been extensively studied in the past decades by scientists at TOLLYS, with a particular focus on TLR3-positive cancers".
About RIBOXX PHARMACEUTICALS
RIBOXX PHARMACEUTICALS is a biotech company developing proprietary Toll-like-receptor (TLR) ligands and RIG-I-like-Receptor (RLR) ligands for applications in cancer immunotherapy. RIBOXX IP portfolio includes 17 PCT patent families so far, with 8 PCT patents granted in EU and/or Japan.
About TOLLYS SAS
TOLLYS SAS is a biotech company developing drugs targeting TLR3-positive cancer cells. TOLLYS SAS has a strong expertise in the design and development of anti-cancer strategies through activation of TLR3-pathway.